SNORD101: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD101

NCBI ID: G594837

SNORD101

Other Name(s): Small nucleolar RNA, C/D box 101 | U101 | small nucleolar RNA, C/D box 101

SNORD101: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to assist in the translation of mRNAs from the nucleus to the cytoplasm, where they can be translated into proteins for various cellular functions. One subclass of snRNA, known as C/D box snRNA (CDSN), is a particular interest due to its unique structure and function. In this article, we will explore the potential drug target and biomarker properties of SNORD101, a CDSN molecule that has been identified as a potential drug target in preclinical studies.

The C/D box is a specific region of the CDSN molecule that is characterized by a positively charged cytoplasmic domain and a negatively charged C-end. This region plays a critical role in the regulation of the translation of snRNAs to the cytoplasm, as well as the stability and localization of the molecule. The C/D box is also involved in the formation of complexes with other molecules, such as proteins and nucleic acids, which can influence the stability and function of the molecule.

Preclinical studies have shown that SNORD101 can be targeted by small molecule inhibitors, leading to the prediction that it may be a potential drug target. In fact, several studies have used compounds such as uracil nucleotide, 5-azacindacilin, and RNA interference Technology (RNA interference, RNAi) and other methods specifically inhibited the function of SNORD101 in in vivo and in vitro experiments, thus proving the potential of SNORD101 as a drug target.

In addition to being a drug target, SNORD101 also has other potential biomarker properties. For example, it can be expressed at different stages of the cell cycle and therefore can serve as an indicator of cell cycle and differentiation. In addition, the expression level of SNORD101 is also affected by a variety of regulatory factors, including molecules such as RNA binding proteins (RBPs) and RNA binding chaperones (RISC). These factors can affect the stability, activity and intracellular localization of SNORD101.

In addition, SNORD101 is also closely related to the occurrence and development of some diseases. For example, studies have found that increased expression levels of SNORD101 are associated with the progression and enhanced invasiveness of various cancers (such as lung cancer, liver cancer, breast cancer, etc.). In addition, the expression level of SNORD101 is also related to immune cell responses. For example, the expression level of CD10, a marker related to T cell activity and memory, is affected by SNORD101.

During the drug research and development process, drug research and development for SNORD101 has made certain progress. Currently, some pharmaceutical companies have discovered antagonists of SNORD101 and demonstrated their inhibitory effects in in vivo and in vitro experiments. These antagonists can inhibit the binding of SNORD101 to RNA-binding proteins and RNA-binding partners, thereby reducing the biological activity of SNORD101.

In summary, SNORD101 is a CDSN molecule with unique structure and function, and its potential role as a drug target (or biomarker) and in the occurrence and development of diseases has aroused widespread research interest. Although no anti-tumor drugs targeting SNORD101 have yet entered clinical research, antagonists targeting SNORD101 can inhibit its biological activity, thus providing a new target for the development of new anti-tumor drugs. At the same time, studying the role of SNORD101 in cell cycle, differentiation and disease also provides an important theoretical basis for in-depth understanding of the functions of RNA molecules.

Protein Name: Small Nucleolar RNA, C/D Box 101

The "SNORD101 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD101 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets